Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$0.31 - $0.45 $4,433 - $6,435
-14,300 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$0.39 - $0.74 $195 - $370
-500 Reduced 3.38%
14,300 $6,000
Q3 2021

Nov 15, 2021

BUY
$0.54 - $2.29 $7,992 - $33,892
14,800 New
14,800 $8,000
Q2 2021

Aug 16, 2021

SELL
$0.97 - $2.39 $192,836 - $475,132
-198,800 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$0.97 - $2.73 $192,836 - $542,724
198,800 New
198,800 $280,000

Others Institutions Holding ITRM

About Iterum Therapeutics plc


  • Ticker ITRM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,233,400
  • Market Cap $14.1M
  • Description
  • Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract inf...
More about ITRM
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.